Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice some appetite reduction within the first week or two after their first Mounjaro injection, though meaningful weight loss typically becomes visible over four to eight weeks. The 2.5mg starting dose is a tolerability dose: its job is to settle your body into treatment, not to produce rapid results. Mounjaro (tirzepatide) is a prescription-only medicine, and a prescriber will assess whether it is right for you before treatment begins. What follows clears up the biggest misunderstanding about how quickly it works — and what that first month is actually for.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common question our prescribers hear in the early weeks of treatment is some version of: "I've had my first injection, why haven't I lost anything yet?" It's a fair question, and the frustration behind it is real. But the expectation of rapid results in week one misunderstands what the first pen is for.
Mounjaro's starting dose of 2.5mg is not a therapeutic dose. Its purpose is adjustment. Your digestive system needs time to adapt to the slowing of gastric emptying and the new hormonal signals coming from two activated receptors, GIP and GLP-1. Push too high too fast and nausea becomes the dominant experience. So the first four weeks exist to protect you from that, not to accelerate weight loss. Knowing this changes how you read those early weigh-ins. A small movement on the scales in week two is a reasonable sign things are working; zero movement is not a sign that they aren't.
The mechanism behind the Mounjaro injection involves both appetite suppression and slower stomach emptying, and both effects take time to become clinically significant at low doses. Most people report their appetite feels different (smaller portions feel satisfying, hunger between meals is quieter) before the scales reflect it.
Week one to two: the most commonly reported change is reduced hunger, particularly the kind of background "noise" that previously made it hard to stop eating at a natural point. Nausea is also most likely here, usually peaking in the first few days after each injection and settling by days four or five. A practical thing worth trying: check in with your hunger levels at your usual meal times in week one and compare them to a normal week. It takes under a minute, and most people find the difference is already noticeable even when the scales aren't moving.
Weeks four to eight: once the dose increases (typically to 5mg after the first four-week pen) appetite suppression deepens and weight loss tends to accelerate. This is the period where most people see the first meaningful change on the scales. Food noise quietens further. Energy intake falls without requiring significant effort because the drive to eat has changed at a biological level, not just through willpower.
The experience around the first injection itself is straightforward for most people (a very fine needle, a few seconds) but the real story unfolds over the weeks that follow. Patience with the early phase pays off significantly later.
SURMOUNT-1, the pivotal phase 3 trial published in the New England Journal of Medicine, ran for 72 weeks across thousands of adults with obesity. Average weight reductions at the highest doses reached around 20–21%. Those headline figures were accumulated gradually, weight loss compounded through the titration schedule rather than arriving in a single early surge.
This is important context for anyone measuring themselves against the trial numbers in the first few weeks. The participants who reached 20% loss did so by staying consistent through the earlier, slower months. The question of how soon Mounjaro works after injection has a nuanced answer: the biological changes begin within hours of the first dose, but the clinical results that matter most build over months, not days.
NICE's appraisal of tirzepatide, TA1026, notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed with a prescriber. Six months is the meaningful evaluation window, not six days.
Not everyone moves along the standard titration path at the same speed. Some people tolerate 5mg earlier; others need a longer stretch at 2.5mg before they're ready. Both are normal and a prescriber decides which applies to you. If nausea at a given dose is persistent rather than settling after the first few days, slowing the titration is sometimes the right clinical call.
Diet during treatment matters too. Mounjaro reduces appetite considerably, but the quality of what you eat still affects how the weight loss goes. Protein adequacy and staying hydrated tend to support the process; neglecting both can make early weeks harder than they need to be. The Mounjaro treatment overview covers what to expect across the full course.
If you're thinking about the cost of treatment alongside this timeline, the context around Mounjaro pricing in the UK is worth reading before you start. And if you have questions about how to store the pen correctly between doses, the fridge storage guidance for Mounjaro sets that out clearly.
For a broader view of weight-loss treatment options, our treatment overview compares what's available. If you're ready to find out whether Mounjaro is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.